Chemistry: molecular biology and microbiology – Treatment of micro-organisms or enzymes with electrical or... – Modification of viruses
Patent
1992-09-22
1996-12-03
Stone, Jacqueline M.
Chemistry: molecular biology and microbiology
Treatment of micro-organisms or enzymes with electrical or...
Modification of viruses
536 245, C12N 1500, C07H 2104
Patent
active
055807674
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to diagnostics, research reagents, and therapies for influenza virus infections. In particular, this invention relates to antisense oligonucleotide interactions with certain viral ribonucleic acids and messenger ribonucleic acids involved in the infection of cells by influenza viruses. Oligonucleotides are provided which hybridize to the viral RNA segments of influenza viruses or to certain mRNA's which encode the NP, M1, M2, NS1, NS2 or other key proteins of influenza viruses, including RNA polymerase, hemagglutinin, nucleoprotein or neuraminidase. Oligonucleotides are also provided which hybridize to certain viral RNA sequences important for RNA splicing or for viral packaging. These oligonucleotides have been found to lead to the modulation of the activity of the RNA; modulation of infection, diagnosis, palliation or therapeutic effect result.
BACKGROUND OF THE INVENTION
Influenza viruses have been a major cause of mortality and morbidity in man throughout recorded history. Epidemics occur at regular intervals which vary widely in severity but which always cause significant mortality and morbidity, most frequently in the elderly population. The cause of influenza epidemics was first attributed to a virus by R. E. Shops, who showed that influenza epidemics could be transmitted with filtered mucus. Influenza viruses are currently divided into three types: A, B, and C, based upon differences in internal antigenic proteins.
An influenza infection produces an acute set of symptoms including headache, cough, fever and general malaise. In severe cases or situations involving pre-existing pulmonary or cardiovascular disease, hospitalization is required. Pneumonia due to direct viral infection or due to secondary bacterial or viral invasion is the most frequent complication. For a review on the clinical aspects of influenza virus infection see Douglas, R. G., New England Journal of Medicine, 322:443-450 (1990).
New strains of influenza caused by antigenic drift appear at regular frequency, usually annually, and begin a cycle of infection which travels around the globe. Little is known about how individual epidemics are initiated. Major new subtypes of influenza appear less frequently but can result in major pandemics.
The most effective way to deal with the influenza virus for the population at risk of severe complications is by prevention. Use of the available influenza vaccine is an effective way to lower the mortality in a population, however due to the ever-changing nature of the virus, the development of a vaccine with the appropriate composition to protect against the currently circulating virus strains is complex and expensive. Moreover, patient compliance in receiving the vaccine is generally very low. Thus large numbers of patients at risk of serious complications from influenza virus go unprotected.
There are several drugs available which have some activity against the influenza virus prophylactically. None, however, are effective against influenza type B. Moreover, they are generally of very limited use therapeutically, and have not been widely used in treating the disease after the onset of symptoms. Accordingly, there is a world-wide need for improved therapeutic agents for the treatment of influenza virus infections.
Prior attempts at the inhibition of influenza virus using antisense oligonucleotides have been reported. Leiter and co-workers have targeted phosphodiester and phosphorothioate oligonucleotides to influenza A and influenza C viruses. Leiter, J., Agrawal, S., Palese, P. & Zamecnik, P. C., Proc. Natl. Acad. Sci. USA, 87:3430-3434(1990). These workers targeted only the polymerase PB1 gene and mRNA in the vRNA 3' region and mRNA 5' region, respectively. Sequence-specific inhibition of influenza A was not observed although some specific inhibition of influenza C was noted. No other influenza virus segments or mRNA's were targeted.
Zerial and co-workers have reported inhibition of influenza A virus by oligonucleotides coincidentally linked to
REFERENCES:
patent: 4689320 (1987-08-01), Kaji
patent: 5004810 (1991-04-01), Draper et al.
patent: 5166195 (1992-11-01), Ecker et al.
patent: 5194428 (1993-03-01), Agrawal
Silva et al (1994) Mol. Pharmocol. 46, 51-57.
Morishita et al (1993) Proced. Natl. Acad. Sci. 90, 8474-8478.
Ratojczak et al (1992) Proc. Natl Acad. Sci 89,11823-11827.
Whitesell et al (1991) Antisense Res. & Develop. 1, 343-350.
Trierr, et al (1993) Biochem Bioph Res. Comm. 190, 952-960.
Bunnell et al (1992) Somat. Cell Molec. Gen. 18, 559-569.
Offensperger et al (1993) EMBO J. 12, 1257-1262.
Simons et al (1992) Nature 359, 67-70.
Cox et al (1988) Virology 167, 554-567.
Burch et al (1991) Clin. Invest. 88, 1190-1196.
Kitajima et al (1992) Science 258, 1792-1795.
Higgins et al (1993) Proced. Natl. Acad. Sci. 90, 9901-9905.
Cohen et al (1994) Sci. Am., Dec., 76-82.
Agrawal et al (1991) Adv. Drug. Delv. Rev. 6, 251-270.
Erlich et al., Searching for Antiviral Materials from Microbial Fermentations, Ann. N.Y. Acad. Sci. 1965, 130:5-16.
Mossman, T., Rapid Colorimetric Assay for Cellurlar Growth and Survival: Application and Proliferation and Cytotoxicity Assays, J. Immunol. Methods, 1983 65:55.
Douglas, R. G., Prophylaxis and Treatment of Influenza, New England Journal of Medicine, 1990 322:443-450.
Leiter, J. et al., Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides, Proc. Natl. Acad. Sci. USA, 87:3430-3434 1990.
Zerial, A. et al., Selective inhiibtion of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent, Nucleic Acids Res., 15:9909-9919 1987.
Kavanov, A. V. et al., A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells, FEBS, 259:327-330 1990.
Rothenberg et al., Oligodeoxynucleotide as Anti-sense Inhibitors of Gene Expression: Therapeutic Implications, J. Natl. Cancer Inst., 81:1539-1544 1989.
Zon, G., Oligonucleotide Analogues as Potential Chemotherapeutic Agents, Pharmaceutical Res., 5:539-549 1988.
Yisraeli et al., Synthesis of Long, Capped Transcripts in Vitro by SP6 and T7 RNA Polymerases, Methods in Enzymology, 180:42-50 1989.
Sanger, F. et al., DNA sequencing with chain-terminating inhibitors, Proc. Natl, Acad. Sci., 74:5463-5467 1977.
Cowsert Lex M.
Ecker David J.
Crouch Deborah
ISIS Pharmaceuticals Inc.
Stone Jacqueline M.
LandOfFree
Inhibition of influenza viruses by antisense oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of influenza viruses by antisense oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of influenza viruses by antisense oligonucleotides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-784665